
Core Laboratories N.V. (CLB)
$
16.42
+0.09 (0.55%)
Key metrics
Financial statements
Free cash flow per share
0.4935
Market cap
764.6 Million
Price to sales ratio
1.4521
Debt to equity
0.7375
Current ratio
2.0749
Income quality
1.1698
Average inventory
56.4 Million
ROE
0.1194
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The weighted average number of diluted shares outstanding is 46,500,000.00 reflecting potential dilution effects. The company incurred an income tax expense of $13,371,000.00 indicating its tax obligations. The cost of revenue for the company is $432,236,000.00 showcasing its production and operational expenses. The company reported an income before tax of $45,896,000.00 showcasing its pre-tax profitability. Furthermore, the weighted average number of shares outstanding is 46,500,000.00 highlighting the company's shareholder base. Core Laboratories N.V. provides essential reservoir description and production enhancement services and products to the oil and gas industry across the United States, Canada, and internationally. Operating through its Reservoir Description and Production Enhancement segments, the company specializes in characterizing petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery from its clients' reservoirs. The Reservoir Description segment offers laboratory-based analytical and field services, including proprietary and joint industry studies, to assess crude oil properties and improve product delivery. In contrast, the Production Enhancement segment focuses on well completions, perforations, stimulations, and production-related services, providing integrated diagnostic services to evaluate and enhance the effectiveness of enhanced oil recovery projects. Additionally, the company markets its products through sales representatives, trade shows, and print advertising, extending its reach through distributors in approximately 50 countries. Founded in 1936 and based in Amstelveen, the Netherlands, Core Laboratories remains a pivotal player in the oil and gas landscape. The stock is affordable at $11.97 suitable for budget-conscious investors. However, the stock has a low average trading volume of 386,661.00 indicating lower market activity. With a market capitalization of $764,570,815.00 the company is classified as a small-cap player. It is a key player in the Oil & Gas Equipment & Services industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Energy sector, driving innovation and growth. Through its dedicated services and extensive market presence, Core Laboratories continues to address the needs of its clients and influence the energy sector's future.
Investing in Core Laboratories N.V. (CLB) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Core Laboratories N.V. stock to fluctuate between $9.72 (low) and $20.36 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2026-03-11, Core Laboratories N.V.'s market cap is $764,570,815, based on 46,563,387 outstanding shares.
Compared to Exxon Mobil Corporation, Core Laboratories N.V. has a Lower Market-Cap, indicating a difference in performance.
Core Laboratories N.V. pays dividends. The current dividend yield is 0.22%, with a payout of $0.01 per share.
To buy Core Laboratories N.V. (CLB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CLB. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Core Laboratories N.V.'s last stock split was 2:1 on 2010-07-09.
Revenue: $526,520,000 | EPS: $0.68 | Growth: 1.49%.
Visit https://www.corelab.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $35.83 (2022-03-08) | All-time low: $9.72 (2025-08-11).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

zacks.com
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?

zacks.com
CLB shows strong international demand, free cash flow generation and a solid financial position, but near-term U.S. land activity challenges and margin pressure could limit growth.

zacks.com
Core Laboratories (CLB) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.22 per share a year ago.

zacks.com
CLB benefits from long-term industry investments and strong acquisitions, though its growth is modest and vulnerable to macroeconomic and geopolitical uncertainties.
zacks.com
CLB beats Q3 earnings estimates on strong Production Enhancement results. However, earnings dip y/y due to the Reservoir Description segment's weakness.

zacks.com
Core Laboratories (CLB) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.25 per share a year ago.

zacks.com
CLB is set to post Q3 earnings amid volatile oil markets, with estimates hinting at lower revenues and profit declines.

zacks.com
Core Laboratories (CLB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
zacks.com
CLB benefits from revenue expansion, proprietary tools & disciplined spending, though flat guidance, low dividends & sector competition remain headwinds.

zacks.com
CLB expands globally with new tech labs and energy transition projects while reducing debt but faces tariff pressures, U.S. market softness and demand volatility risks.
See all news